01.12.2014 | Research article | Ausgabe 1/2014 Open Access

Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain
- Zeitschrift:
- BMC Palliative Care > Ausgabe 1/2014
Electronic supplementary material
Competing interest
Authors’ contribution
Background
Methods
Patient eligibility
Study design and treatment
Statistical analysis
Results
Sex
|
|
Male/Female
|
43/6
|
Age (years-old)
|
69.0 ± 6.9
|
Body mass index (kg/m
2)
|
20.4 ± 4.9
|
Cancer (Histology)
|
|
Lung Cancer (Ad/SQ/SCLC/Others)
|
48 (26/14/4/4)
|
Mesothelioma
|
1
|
Stage
|
|
IIB/IIIA/IIIB/IV
a
|
1/4/7/37
a
|
ECOG PS
|
|
0-1/2/3/4
|
28/13/5/3
|
Pain location
b
|
|
Neck-shoulder/Upper limb/Chest/Hypochondrium/Lower back/Glutaeus to thigh
|
|
4/2/32/1/7/5
|
|
Pain causes
b
|
|
Distant metastasis (bone)/Invasion/Pleural dissemination
|
|
22 (17)/18/11
|
|
Duration of cancer pain (months)
|
|
mean ± SD
|
4.3 ± 4.4
|
median (range)
|
2 (0.27–18)
|
Duration of controlled-release oxycodone administration (months)
|
|
mean ± SD
|
2.0 ± 4.3
|
median (range)
|
0.6 (0.1 - 19.7)
|
Fentanyl patch treatment site
|
|
day 1
|
|
Hospitalized/Outpatient
|
40/9
|
day 8
|
|
Hospitalized/Outpatient
|
32/17
|
day 15
|
|
Hospitalized/Outpatient
|
22/27
|
Concomitant systemic chemotherapy
|
|
Yes/No
|
25/24
|
Concomitant radiotherapy
|
|
Yes/No
|
12/37
|
Day 1
|
Day 8
|
Day 15
|
|
---|---|---|---|
mean ± SD
|
2.7 ± 0.9
|
2.4 ± 0.9
|
2.3 ± 0.9
|
median (range)
|
3 (1 - 5)
|
2 (1 - 5)
|
2 (1 - 5)
|
vs. day 1
b
|
n.s.
|
n.s.
|
|
Patients’ distribution (N)
|
|||
1. Very satisfied
|
2
|
5
|
9
|
2. Satisfied
|
18
|
24
|
19
|
3. Neither
|
20
|
12
|
14
|
4. Dissatisfied
|
4
|
4
|
3
|
5. Very dissatisfied
|
2
|
1
|
1
|
Day 1
|
Day 8
|
Day 15
|
||||
---|---|---|---|---|---|---|
Opioids
|
Oral oxycodone
|
Fentanyl patch
|
Fentanyl patch
|
|||
Dose
|
||||||
Mean ± SD
|
14.7 ± 4.1 mg/day
|
13.7 ± 4.8 μg/h
|
15.5 ± 6.0 μg/h
|
|||
Patients’ distribution (N)
|
10 mg/day
|
18
|
12.5 μg/h
|
44
|
12.5 μg/h
|
38
|
15 mg/day
|
16
|
18.8 μg/h*
|
1
|
18.8 μg/h*
|
1
|
|
20 mg/day
|
15
|
25.0 μg/h
|
3
|
25.0 μg/h
|
9
|
|
37.5 μg/h
|
1
|
37.5 μg/h
|
1
|
Day 1
|
Day 8
|
Day 15
|
p-value
a
|
|
---|---|---|---|---|
NRS pain intensity (N = 49)
|
0.15
|
|||
Mean ± SD
|
2.2 ± 1.4
|
2.1 ± 1.5
|
1.9 ± 1.4
|
|
Median (range)
|
2 (0 - 6)
|
2 (0 - 7)
|
2 (0 - 6)
|
|
NRS 0 – 3 / ≥ 4
|
43/6
|
41/8
|
43/6
|
|
Immediate-release oxycodone (mg / day) (N = 48)
b
|
0.36
|
|||
Mean ± SD
|
1.9 ± 2.2
|
2.7 ± 3.5
|
2.2 ± 2.7
|
|
Median (range)
|
2.5 (0 - 10)
|
2.5 (0 - 15)
|
1.75 (0 - 10)
|
N
|
Day 1
|
Day 8
|
Day 15
|
p-value
a
|
|
---|---|---|---|---|---|
Sleepiness
|
45
|
0.004
|
|||
Mean ± SD
|
1.2 ± 0.7
|
0.9 ± 0.6
|
0.73 ± 0.8
|
||
Median (range)
|
1 (0 - 3)
|
1 (0 - 2)
|
1 (0 - 3)
|
||
vs. day 1
b
|
n.s.
|
<0.05
|
|||
Nausea
|
49
|
0.87
|
|||
Mean ± SD
|
0.4 ± 0.8
|
0.4 ± 0.7
|
0.3 ± 0.6
|
||
Median (range)
|
0 (0 - 3)
|
0 (0 - 3)
|
0 (0 - 2)
|
||
Vomit
|
49
|
0.66
|
|||
Mean ± SD
|
0.1 ± 0.6
|
0.2 ± 0.6
|
0.1 ± 0.5
|
||
Median (range)
|
0 (0 - 3)
|
0 (0 - 3)
|
0 (0 - 2)
|
||
Constipation
|
48
|
0.08
|
|||
Mean ± SD
|
0.5 ± 0.7
|
0.3 ± 0.5
|
0.3 ± 0.5
|
||
median (range)
|
0 (0 - 3)
|
0 (0 - 2)
|
0 (0 - 2)
|
||
Defecation number (/ day)
|
49
|
0.85
|
|||
Mean ± SD
|
1.1 ± 1.0
|
1.0 ± 0.8
|
1.0 ± 0.7
|
||
Median (range)
|
1 (0 - 4)
|
1 (0 - 4)
|
1 (0 - 4)
|
||
Epworth Sleep Scale
|
49
|
0.96
|
|||
Mean ± SD
|
6.3 ± 4.0
|
6.1 ± 4.2
|
6.0 ± 4.2
|
||
Median (range)
|
6 (0 - 16)
|
5 (0 - 18)
|
5 (0 - 19)
|